Takes

Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star

  • by

Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration. Merck KGaA exercises its option to license a preclinical program in its existing agreement with F-star Merck KGaA will be… Read More »Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star